We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

67 hedge funds and large institutions have $218M invested in Biotech Acquisition Company Class A Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

0% more capital invested

Capital invested by funds: $218M → $218M (+$166K)

0% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 13

12% less funds holding

Funds holding: 76 → 67 (-9)

50% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 18

Holders
67
Holders Change
-9
Holders Change %
-11.84%
% of All Funds
1.13%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
9
Increased
13
Reduced
13
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$19.8M
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$7.37M
3
GCL
Glazer Capital LLC
New York
+$6.24M
4
RL
RPO LLC
Connecticut
+$4.5M
5
AA
AQR Arbitrage
Connecticut
+$2.45M

Top Sellers

Rank Fund Capital Flow
1
KC
Kryger Capital
United Kingdom
-$8.33M
2
Citadel Advisors
Citadel Advisors
Florida
-$7.35M
3
MP
Mangrove Partners
Connecticut
-$4.93M
4
DCM
DG Capital Management
New York
-$4.43M
5
PC
Periscope Capital
Ontario, Canada
-$2.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
26
Arena Capital Advisors
California
$2.97M – – –
Jane Street
27
Jane Street
New York
$2.97M +$1.62M +165,509 +123%
CH
28
CVI Holdings
Delaware
$2.9M +$89.6K +9,137 +3%
WAM
29
Wolverine Asset Management
Illinois
$2.48M +$835K +85,170 +51%
Deutsche Bank
30
Deutsche Bank
Germany
$2.48M – – –
OAC
31
OMERS Administration Corp
Ontario, Canada
$2.44M – – –
WAM
32
Weiss Asset Management
Massachusetts
$2.33M -$1.13M -114,752 -33%
Goldman Sachs
33
Goldman Sachs
New York
$2.3M -$8.82K -900 -0.4%
RCM
34
Rivernorth Capital Management
Florida
$2.19M – – –
Alyeska Investment Group
35
Alyeska Investment Group
Illinois
$1.49M – – –
PMAM
36
Picton Mahoney Asset Management
Ontario, Canada
$1.49M – – –
CAC
37
Cowen and Company
New York
$1.49M +$1.47M +150,000 New
Citadel Advisors
38
Citadel Advisors
Florida
$1.45M -$7.35M -749,281 -84%
TCM
39
Tenor Capital Management
New York
$1.42M – – –
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$1.3M – – –
Walleye Capital
41
Walleye Capital
New York
$1.17M +$352K +35,907 +44%
SCM
42
Shaolin Capital Management
Florida
$1.06M – – –
LP
43
LMR Partners
United Kingdom
$990K – – –
CS
44
Clear Street
New York
$990K +$981K +100,000 New
HF
45
HRT Financial
New York
$914K +$906K +92,383 New
Walleye Trading
46
Walleye Trading
New York
$787K – – –
YCM
47
Yakira Capital Management
Connecticut
$533K – – –
COPPSERS
48
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$495K – – –
LC
49
Littlejohn & Co
Connecticut
$495K – – –
CCA
50
Castle Creek Arbitrage
Colorado
$493K -$490K -50,000 -50%
1
2
3 4

BIOT Hedge Fund Activity: Q2 2022 in Review

67 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q2 2022, worth a combined $218M — up 0.08% from $218M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of BIOT and 9 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 13 added.

The largest buyer was JP Morgan Chase, opening a new position worth an estimated $19.8M. The largest seller was Kryger Capital, exiting entirely with an estimated $8.33M sold.

  • 67 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q2 2022, down from 76 in Q1 2022.
  • Funds reported $218M of Biotech Acquisition Company Class A Ordinary Shares stock for Q2 2022, up 0.08% quarter-over-quarter.
  • 9 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q2 2022 and 18 closed out, a net change of -9 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q2 2022 was JP Morgan Chase, an estimated $19.8M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q2 2022 was Kryger Capital, an estimated $8.33M sold.

Based on aggregated 13F filings for Q2 2022.